On the public citation graph

Expansion of the S-CN-DABO Scaffold to Exploit the Impact on Inhibitory Activities Against the Non-Nucleoside HIV-1 Reverse Transcriptase

https://doi.org/10.2139/ssrn.4097916
0 signed · 54 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/ardp.200400961openalex-extracted
Non‐nucleoside HIV Reverse Transcriptase Inhibitors, Part 6[1]: Synthesis and Anti‐HIV Activity of Novel 2‐[(Arylcarbonylmethyl)thio]‐6‐arylthio DABO Analogues
inferredcites →https://doi.org/10.1002/cbdv.200890008openalex-extracted
Non‐Nucleoside HIV‐1 Reverse‐Transcriptase Inhibitors. Part 10
inferredcites →https://doi.org/10.1002/med.21445openalex-extracted
Development of Safe Drugs: The hERG Challenge
inferredcites →https://doi.org/10.1002/med.21760openalex-extracted
Druggability modification strategies of the diarylpyrimidine‐type non‐nucleoside reverse transcriptase inhibitors
inferredcites →https://doi.org/10.1006/abio.1997.2177openalex-extracted
Characterization of PicoGreen Reagent and Development of a Fluorescence-Based Solution Assay for Double-Stranded DNA Quantitation
inferredcites →https://doi.org/10.1006/viro.1993.1027openalex-extracted
HIV-1-Specific Reverse Transcriptase Inhibitors Show Differential Activity against HIV-1 Mutant Strains Containing Different Amino Acid Substitutions in the Reverse Transcriptase
inferredcites →https://doi.org/10.1016/0166-0934(88)90134-6openalex-extracted
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds
inferredcites →https://doi.org/10.1016/0223-5234(92)90009-popenalex-extracted
Synthesis, antimicrobial and antiviral activities of isotrimethoprim and some related derivatives
inferredcites →https://doi.org/10.1016/j.apsb.2019.09.007openalex-extracted
Improving the positional adaptability: structure-based design of biphenyl-substituted diaryltriazines as novel non-nucleoside HIV-1 reverse transcriptase inhibitors
inferredcites →https://doi.org/10.1016/j.apsb.2019.11.010openalex-extracted
Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years
inferredcites →https://doi.org/10.1016/j.bioorg.2004.05.007openalex-extracted
Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones
inferredcites →https://doi.org/10.1016/j.bmc.2008.01.039openalex-extracted
Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors
inferredcites →https://doi.org/10.1016/j.bmc.2011.05.024openalex-extracted
Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors
inferredcites →https://doi.org/10.1016/j.bmc.2013.08.040openalex-extracted
Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: Synthesis, biological investigation and molecular modeling studies
inferredcites →https://doi.org/10.1016/j.bmcl.2004.04.008openalex-extracted
5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series
inferredcites →https://doi.org/10.1016/j.cclet.2019.11.020openalex-extracted
Fragment-based discovery of sulfur-containing diarylbenzopyrimidines as novel nonnucleoside reverse transcriptase inhibitors
inferredcites →https://doi.org/10.1016/j.coph.2020.09.017openalex-extracted
Recent discoveries in HIV-1 reverse transcriptase inhibitors
inferredcites →https://doi.org/10.1016/j.coph.2020.10.005openalex-extracted
Design strategies for long-acting anti-HIV pharmaceuticals
inferredcites →https://doi.org/10.1016/j.ejmech.2008.06.028openalex-extracted
Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors
inferredcites →https://doi.org/10.1016/j.ejmech.2018.07.035openalex-extracted
6-Biphenylmethyl-3-hydroxypyrimidine-2,4-diones potently and selectively inhibited HIV reverse transcriptase-associated RNase H
inferredcites →https://doi.org/10.1016/j.ejmech.2020.112290openalex-extracted
hERG toxicity assessment: Useful guidelines for drug design
inferredcites →https://doi.org/10.1016/j.ejmech.2021.113868openalex-extracted
Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel
inferredcites →https://doi.org/10.1016/s0213-005x(09)73216-1openalex-extracted
Interacciones medicamentosas de etravirina
inferredcites →https://doi.org/10.1016/s1359-6446(04)03278-7openalex-extracted
Predictive in silico modeling for hERG channel blockers
inferredcites →https://doi.org/10.1021/acs.jmedchem.0c00117openalex-extracted
Structure-Based Bioisosterism Yields HIV‑1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00128openalex-extracted
Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from N-Alkylation to Methyl Hopping on the Pyrimidine Ring
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c00708openalex-extracted
Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c01676openalex-extracted
Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK
inferredcites →https://doi.org/10.1021/acs.jmedchem.1c01758openalex-extracted
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b00140openalex-extracted
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b00497openalex-extracted
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b00983openalex-extracted
Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b01979openalex-extracted
Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family
inferredcites →https://doi.org/10.1021/acs.jmedchem.9b01446openalex-extracted
Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles
inferredcites →https://doi.org/10.1021/acschemneuro.8b00605openalex-extracted
Neuroprotective Effect of Swertiamain on Cerebral Ischemia/Reperfusion Injury by Inducing the Nrf2 Protective Pathway
inferredcites →https://doi.org/10.1021/acsinfecdis.7b00275openalex-extracted
2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis : Structure–Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization
inferredcites →https://doi.org/10.1021/acsmedchemlett.6b00025openalex-extracted
Design and Synthesis of 2-Alkylpyrimidine-4,6-diol and 6-Alkylpyridine-2,4-diol as Potent GPR84 Agonists
inferredcites →https://doi.org/10.1021/jm00017a010openalex-extracted
Preparation and anti-HIV-1 activity of Thio Analogues of Dichydroalkoxybenzyloxopyrimidines
inferredcites →https://doi.org/10.1021/jm00378a016openalex-extracted
Novel pyrimidine and 1,3,5-triazine hypolipemic agents
inferredcites →https://doi.org/10.1021/jm010853hopenalex-extracted
Structure-Based Design, Synthesis, and Biological Evaluation of Conformationally Restricted Novel 2-Alkylthio-6-[1-(2,6-difluorophenyl)alkyl]- 3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase
inferredcites →https://doi.org/10.1021/jm0309856openalex-extracted
Computer-Aided Design, Synthesis, and Anti-HIV-1 Activity in Vitro of 2-Alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)- ones as Novel Potent Non-Nucleoside Reverse Transcriptase Inhibitors, Also Active Against the Y181C Variant
inferredcites →https://doi.org/10.1021/jm061167ropenalex-extracted
Synthesis and Anti-HIV-1 Activity Evaluation of 5-Alkyl-2-alkylthio-6-(arylcarbonyl or α-cyanoarylmethyl)-3,4-dihydropyrimidin-4(3H)-ones as Novel Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors
inferredcites →https://doi.org/10.1021/jm4017174openalex-extracted
Rapid Identification of Keap1–Nrf2 Small-Molecule Inhibitors through Structure-Based Virtual Screening and Hit-Based Substructure Search
inferredcites →https://doi.org/10.1038/nprot.2007.517openalex-extracted
Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later
inferredcites →https://doi.org/10.1038/nrd2336openalex-extracted
HIV drug development: the next 25 years
inferredcites →https://doi.org/10.1039/c3md00247kopenalex-extracted
Synthesis and biological evaluation of new conformationally restricted S-DABO hybrids as non-nucleoside inhibitors of HIV-1 reverse transcriptase
inferredcites →https://doi.org/10.1039/c7ob02828hopenalex-extracted
Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored “hydrophobic channel”
inferredcites →https://doi.org/10.1073/pnas.90.15.6952openalex-extracted
Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific…
inferredcites →https://doi.org/10.1080/13543776.2017.1303046openalex-extracted
Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1
inferredcites →https://doi.org/10.1124/dmd.31.8.1005openalex-extracted
IN VITRO DRUG INTERACTIONS OF CYTOCHROME P450: AN EVALUATION OF FLUOROGENIC TO CONVENTIONAL SUBSTRATES
inferredcites →https://doi.org/10.1124/mol.61.2.400openalex-extracted
Chimeric Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Reverse Transcriptases: Role of the Subunits in Resistance/Sensitivity to Non-Nucleoside Reverse Transcriptase Inhibitors
inferredcites →https://doi.org/10.1128/cmr.00102-15openalex-extracted
Approved Antiviral Drugs over the Past 50 Years
inferredcites →https://doi.org/10.1128/jvi.67.9.5353-5359.1993openalex-extracted
Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy
inferredcites →https://doi.org/10.2174/092986711795843209openalex-extracted
Recent Advances in the DABOs Family as Potent HIV-1 non-Nucleoside Reverse Transcriptase Inhibitors
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.